Showing results (191-200 of 270) with videos related to
Sort By:
Pageof 27
Lung Cancer (Auckland, N.Z.)|June 28, 2024
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus SurveySai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2026
Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutations with increased responsiveness to second- vs third-generation tyrosine kinase inhibitorsXimeng Liu, Moses Stamboulian, Maxime Borgeaud, et al.Frontiers in Oncology|July 26, 2021
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb StudiesAntonio Passaro, Filippo de Marinis, Hai-Yan Tu, et al.Cancers|July 27, 2022
Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung AdenocarcinomaLingzhi Hong, Whitney E Lewis, Monique Nilsson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2023
ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLCNatalie I Vokes, Ana Galan Cobo, Margarita Fernandez-Chas, et al.Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.Cancers|May 14, 2025
Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil ModelHui Li, Morteza Salehjahromi, Myrna C B Godoy, et al.Translational Lung Cancer Research|November 19, 2020
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancerIlaria Attili, Laura Bonanno, Niki Karachaliou, et al.ERJ Open Research|June 24, 2026
Immunotherapy-related interstitial lung disease: a call to improve risk stratification and diagnostic consistencyLaura Fabbri, Katerina Antoniou, Torsten Gerriet Blum, et al.JTO Clinical and Research Reports|March 31, 2025
Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNASimon Heeke, Saumil Gandhi, Hai T Tran, et al.Pageof 27